New PrEP Results Exceed HIV Researchers' High Expectations | |
 | Two studies found that PrEP -- whether used daily or "on demand" -- reduced HIV risk by 86% among very sexually active MSM. |
Vaginal HIV Prevention Gel Fails in Major Study | |
Disappointing new study results have dealt a serious blow to hopes for a vaginal gel to help women protect themselves from HIV infection. |  |
Inflammation Persists Despite Very Early HIV Treatment | |
 | Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy. |
Hepatitis C Treatment Discount Deals Tie Doctors' Hands | |
Why are discount deals making it harder for some doctors to prescribe hepatitis C treatment? |  |
An interview series exploring key issues in HIV care.
Key Issues Affecting the Care of HIV-Positive Adolescents
An Interview With John Steever, M.D.
Unraveling the Impact of Trauma on People With HIV -- and Their Care Providers
An Interview With Edward Machtinger, M.D.
The Future of HIV Prevention, Treatment and Care
An Interview With Mark Harrington
New HIV Heart Disease Findings Not as Dire as They May Seem
An Interview With David Alain Wohl, M.D.
How to Make HIV "Take Up Knitting"
An Interview With David Harrich, Ph.D.
A blog featuring professionals on the frontlines of HIV treatment, prevention and care.
In Childhood Vaccine Controversy, an Indirect Lesson for HIV/AIDS Advocates
A Blog Entry by Mitchell Warren
To Russia (and Eastern Europe and Central Asia), With Love
A Blog Entry by Benjamin Young, M.D., Ph.D.
The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies
A Blog Entry by Brook K. Baker
New HCV Option Effective, Safe, Well-Tolerated -- and Use Will Likely Be Driven by Payors
A Blog Entry by Paul E. Sax, M.D.
5 ID/HIV Things to Be Grateful for This Holiday Season, 2014 Edition
A Blog Entry by Paul E. Sax, M.D.
Efavirenz Dosed at 400 mg Provides Adequate Cerebrospinal Fluid Exposure
Ben Young: CROI 2015 Data Bolster the Call for Initiative to End HIV/AIDS Epidemic
Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients
Global Fund Releases End-of-2014 Numbers
Partners PrEP Demo Project: Near Elimination of HIV Transmission With ART and PrEP
Inflammation Persists Despite Very Early HIV Treatment
Vaginal HIV Prevention Gel Fails in Major Study
New PrEP Results Exceed HIV Researchers' High Expectations
India Rejects Gilead's Patent Application for Sofosbuvir
Tribute to Joep Lange Opens Up CROI 2015
AVAC Calls for Rapid Response to New Antiretroviral-Based HIV Prevention Data Presented at CROI 2015
Three-Drug Regimen Superior for Preventing Vertical Transmission in the PROMISE Study
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
